Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD and a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first implant product aimed at improving cheek smoothness [1] - CICC expresses optimism regarding the product's approval, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - The long-term outlook from CICC suggests that the company's research and development strength, brand recognition, and team cohesion remain solid [1] - As the cosmetics market recovers and the contribution from aesthetic medicine increases, CICC recommends paying attention to investment opportunities in the company [1]
港股异动 | 巨子生物(02367)盘中涨超8% 全球首个注射用重组胶原蛋白和透明质酸钠复合溶液获批